Clinical pharmacology of AMG 181, a gut-specific human anti-α4β7 monoclonal antibody, for treating inflammatory bowel diseases.
about
Integrin-based therapeutics: biological basis, clinical use and new drugsCurrent stage in inflammatory bowel disease: What is next?Designing biologic selectivity for inflammatory bowel disease--role of vedolizumabReceptor occupancy assessment by flow cytometry as a pharmacodynamic biomarker in biopharmaceutical developmentPrediction of clinical pharmacokinetics of AMG 181, a human anti-α 4 β 7 monoclonal antibody for treating inflammatory bowel diseasesEmerging Treatment Options in Mild to Moderate Ulcerative Colitis.New targeted therapies such as anti-adhesion molecules, anti-IL-12/23 and anti-Janus kinases are looking toward a more effective treatment of inflammatory bowel disease.Recommendations for the development and validation of flow cytometry-based receptor occupancy assays.Emerging therapeutic targets and strategies in Crohn's disease.Integrin antagonists as potential therapeutic options for the treatment of Crohn's disease.Frontiers in Drug Research and Development for Inflammatory Bowel Disease.A weighted method for estimation of receptor occupancy for pharmacodynamic measurements in drug development.Emerging Therapies for Inflammatory Bowel Disease
P2860
Q26773026-E5FA695B-0DE3-4978-8D90-42A9947583BFQ26777429-2B0E0B27-E82F-43A7-A2C5-50DB1D3A2DFEQ28083872-64488449-3253-4019-BB14-A4E68FED443AQ28084276-B2709C1E-73EE-44E2-ADE7-3D92AFD7E2DBQ35049579-8F1C2718-084D-42B8-93F5-CE9C21798682Q36172156-290ACC3C-F3E0-4792-9CD9-3843F6A59BF4Q38293802-15404B28-9BD7-4626-9160-EE7BA29F2EE7Q38632834-9EF83882-7CF3-4B15-98E3-A94C540D88B3Q38696392-43D1B14F-E42E-4648-86BF-665062C74329Q38715286-BC1ABB54-5C4F-4F5E-9A8A-210821C47B85Q39424463-F1E6F9BB-A760-4D22-8780-C915948A53A3Q40703054-3B524D01-C5CF-4888-AC8C-8045149644FAQ58099968-EBDF5ADD-DBA7-454E-99A1-5BA8877A3BF7
P2860
Clinical pharmacology of AMG 181, a gut-specific human anti-α4β7 monoclonal antibody, for treating inflammatory bowel diseases.
description
2014 nî lūn-bûn
@nan
2014 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Clinical pharmacology of AMG 1 ...... g inflammatory bowel diseases.
@ast
Clinical pharmacology of AMG 1 ...... g inflammatory bowel diseases.
@en
Clinical pharmacology of AMG 1 ...... g inflammatory bowel diseases.
@nl
type
label
Clinical pharmacology of AMG 1 ...... g inflammatory bowel diseases.
@ast
Clinical pharmacology of AMG 1 ...... g inflammatory bowel diseases.
@en
Clinical pharmacology of AMG 1 ...... g inflammatory bowel diseases.
@nl
prefLabel
Clinical pharmacology of AMG 1 ...... g inflammatory bowel diseases.
@ast
Clinical pharmacology of AMG 1 ...... g inflammatory bowel diseases.
@en
Clinical pharmacology of AMG 1 ...... g inflammatory bowel diseases.
@nl
P2093
P2860
P921
P356
P1476
Clinical pharmacology of AMG 1 ...... g inflammatory bowel diseases.
@en
P2093
Anthony M Treacy
Barbara A Sullivan
Christine D Krill
Christine M Evangelista
David R Doherty
Dominic C Borie
Graham L Radford-Smith
Jane M Andrews
Jason M Gow
P2860
P304
P356
10.1111/BCP.12418
P407
P577
2014-12-01T00:00:00Z